BioPlus바이오플러스
099430 · KOSDAQ · ₩099430 · 바이오플러스
₩3,200▼ ₩210 (6.16%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩91B | ₩66B | ₩65B | ₩57B | ₩37B |
| Cost of sales | ₩30B | ₩24B | ₩25B | ₩23B | ₩14B |
| Gross profit | ₩61B | ₩43B | ₩40B | ₩34B | ₩24B |
| Operating income | ₩15B | ₩24B | ₩28B | ₩25B | ₩18B |
| Net income | ₩20B | ₩18B | ₩27B | ₩21B | ₩11B |
| Net income to shareholders | ₩15B | ₩14B | ₩26B | ₩21B | ₩11B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩285B | ₩264B | ₩173B | ₩147B | ₩88B |
| Current assets | ₩65B | ₩77B | ₩97B | ₩106B | ₩54B |
| Cash and equivalents | ₩21B | ₩39B | ₩46B | ₩18B | ₩41B |
| Total liabilities | ₩90B | ₩117B | ₩35B | ₩32B | ₩7.9B |
| Current liabilities | ₩77B | ₩112B | ₩11B | ₩9.5B | ₩7.5B |
| Borrowings | ₩56B | ₩53B | ₩1.9B | — | ₩1.5B |
| Total equity | ₩195B | ₩148B | ₩138B | ₩115B | ₩81B |
| Shareholders' equity | ₩175B | ₩133B | ₩128B | ₩113B | ₩79B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩15B | ₩22B | ₩16B | ₩13B | ₩13B |
| Capital spending | ₩47B | ₩95B | ₩21B | ₩6.5B | ₩15B |
| Free cash flow | −₩32B | −₩73B | −₩5.1B | ₩6.8B | −₩2B |
| Dividends paid | ₩2.9B | — | — | — | — |
Consolidated where available. Amounts in won.
Also known as: BioPlus / 바이오플러스 / 099430 / KRX:099430
Source: KRX statistical information